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orre pondence r ce abner, M D , ro e treet, , o ton, Ma ac ett , e ep one --a ---Mai bc abner partner or ecei ed pri , accepted for p b ication pri , p aMed re -ttp d doi or t eonco oi t -e concept of er ona i ed Medicine a captured the imagination of the world medical community in general, and the community of oncologi t in particular he e ential notion i that molecular tests, or biomarkers, of patient and or tumor can match the patient to the most effecti e and least to ic treatment, and thereby impro e outcomes, a oid useless to icity, reduce costs of care, and place therapeutics on a more rational basis b iously, the care of patients in all fields, including oncology, has been personali ed for decades, as doctors tailor treatment to many aspects of the indi idual patient s circumstance social, financial, and medical factors all playing a role owe er, the newest iteration of personali ed medicine, and perhaps it is a misnomer, focuses on treatment tailored to the specific genetic causes underlying the disease owhere has the concept of therapy based on genetics caught tighter hold than in cancer research, where substantial ad ances in treatment ha e resulted from identifying specific somatic mutations in tumors and treating with drugs that target those mutations his paradigm has been successful for treating unique molecular subsets of breast cancer (trastuumab , chronic myeloid leukemia (imatinib and congeners , gastrointestinal stromal tumors (imatinib , melanoma (the inhibitor emurafenib ( , and non-small cell lung cancer (the and Minhibitors n the past decade, the number of successful targeted therapies, with attendant mutational biomarkers, has steadily increased i new cancer drugs, targeted for specific genetic mutations, were appro ed for marketing in ust the past two years or each of these drugs, a specific biomarker test selects the drug for the patient list of commonly used molecular tests and their appro ed indications is pro ided in able Biomarkers used to select patients for new treatments ha e guided patient selection in many successful drug trials in recent years and ha e led to a sea change in the process for drug appro al ri otinib was appro ed three years after entering the clinic, based on one phase trial and a single confirmatory phase study in Mtranslocated ot only has the use of biomarkers accelerated the pace of cancer drug de elopment the disco ery of unique genomic subsets of common tumors has changed our basic concept of cancer o longer are histological categories of ma or tumors sufficient to define treatment ung, breast, and colon cancer, as well as melanoma, are now recogni ed as collections of molecular subsets of cancer, with each subset ha ing its own natural history and responsi eness to treatment n non-small cell lung cancer ( , mutation, Mtranslocation, kinase translocation, mutation, and potentially a number of other categories of disease define therapeutically rele ant subsets of disease he implementation of personali ed cancer therapy rests on the a ailability of genomic tumor testing, both for rapid drug de elopment and for clinical practice t present, probably no more than of cancer patients could meaningfully profit from genetic profiling for commerciali ation, including those for mutations and Mtranslocations. or M patients and researchers, the T pro ides the e pertise for de eloping new genotyping assays that ser e as selecti e biomarkers for e perimental drug trials and for unappro ed indications of appro ed drugs. Thus, the T has significantly enhanced our ability to attract early phase trials for targeted therapies. Promising trials are now in progress targeting tumors with O translocations, and breast cancers and other tumors with phosphoinositide-kinase pathway mutation, deletion or amplifications.
ollowing the lead of M , many of the nation s comprehensi e cancer centers, including anderbilt, Dana arber, MD nderson, Memorial loan ettering, the untsman ancer enter, and Ohio tate ha e established in-house T -like facilities. recent ew ork Times article details the proliferation of hospital-based genotyping centers throughout Manhattan . or many cancer centers, these facilities pro ide assays for testing tumors from , melanoma, and other patients. These centers ha e a ariable and selecti e repertoire of genomic tests primarily aimed at supporting e perimental studies. n con ersations with other cancer center in estigators, it is clear that most of these facilities are focused on research pro ects. ew centers currently ha e in place the capacity for routine genotyping of patients' tumors for all appro ed indications, and to our knowledge, none pro ide this ser ice to outside in estigators or clinicians on a regional basis. ith the de elopment of rapid and ine pensi e technology for selecti e gene sequencing and e en whole e ome sequencing, it is likely that the ma or research centers will e pand tumor genetic testing to include a higher percentage of their patients in the ne t few years.
i en the growing importance of tumor profiling for routine practice and for e perimental trials, how widely a ailable is this technology n the nited tates, there are currently serious gaps in our ability to deli er routine personali ed treatment for all cancer patients. ompanion assays for D -appro ed drugs are now a ailable through commercial sources such as Bioference abs, oundation Medicine, bbott Molecular Diagnostics, oche Molecular Diagnostics, the need to select patients for clinical trials based on test results. The trend is unmistakable. Oncology research, and the practice of medical oncology in the coming decade will increasingly depend on access to molecular assays. hat is the current a ailability of testing tumor genetics in the nited tates ome hospitals are addressing this need by establishing their own genotyping facilities. The ancer enter at Massachusetts eneral ospital (M set up the first such ser ice in , the Translational esearch aboratory (T , and focused its effects on screening for genes and specific mutations and translocations prominent in melanoma, lung, breast, and colorectal cancer. The assays it currently offers are primarily P -based tests for mutations or -based assays for translocations and amplifications. ith the de elopment of rapid D sequencing, the approach will change to deep sequencing of cancer-related genes. The ser ice at M is appro ed. esults are recorded in the patient charts. eimbursement for home-grown assays is ariable. M bills insurance companies for its ser ices in cases for which the result will determine eligibility for an appro ed therapy. The hospital recei es ariable reimbursement, depending on the insurer and the clinical setting, and these funds ha e defrayed the cost of running the ser ice. ecent changes in Medicare coding for genetic tests ha e created uncertainty about future reimbursements. t is clear that most insurers, including Medicare, will only pay for assays that are tied to therapeutic decisions in ol ing appro ed agents. The actual costs of performing multiple assays for the actionable cancer mutations will likely lie in the range of , -, for each patient, but will depend on the scope of the analysis and the technology in ol ed. ith the rapid e olution of sequencing technology, costs will likely decrease with time. onetheless, the e isting M facility and others like it, such as the facilities at Dana arber and anderbilt, ha e pro en increasingly useful for routine care, as more and more targeted drugs ha e been appro ed for routine clinical practice. n addition to the benefits afforded for clinical practice, the T facility supports clinical research and has de eloped a number of no el assays, some of which ha e been adopted The Oncologist ® Personali ed Medicine ype or eality lphaMed Press and other pro iders, and, depending on the specific indication, the costs may or may not be reimbursed by arious insurers or by Medicare. or uninsured or underinsured patients, the commercial testing option is e pensi e, or not a ailable. f a researcher wishes to test for the presence of a mutation that would place the patient on a clinical trial, the costs of the test are likely not to be co ered by insurance.
or appro ed drugs, access to testing is incomplete. Pfi er oncology director Mace othenberg estimates that only of . . patients with -translocated are currently recei ing cri otinib during the course of their illness. The reasons for this deficiency are unknown, but othenberg speculates that se eral factors are belie ed to play a role, including ( the e pense and time required to purchase the test from a commercial source, ( the cost of the assay, which may or may not be reimbursed by insurance, ( the need to pro ide an adequate tissue sample for testing, and ( the lack of physician awareness of superiority of cri otinib treatment as compared to chemotherapy. The results of a randomi ed trial demonstrating that superiority will soon be published . side from this anecdote about cri otinib and mutation, at this time we do not ha e accurate information on the percentage of lung cancer patients (smoker or nonsmoker in the . . who are screened for mutation, or the percentage of melanoma patients who are screened for B mutation. Our suspicion is that chemotherapy is tried first in many ad anced patients, despite data from phase randomi ed trials demonstrating the superiority of inhibitors for patients with -mutant tumors . imilarly, interferon or -is likely tried first in many melanoma patients for the reasons enumerated abo e. tudies are needed to confirm these suspicions.
Beyond the a ailability of tests for appro ed indications, the majority of cancer patients who are cared for in community practices (not at a major cancer center will likely ha e ery limited access to genomic tests that can direct them to clinical trials of promising new agents when con entional treatment fails. nlike the . ., other countries ha e taken the lead in making genetic profiling of cancer a ailable on a national basis. ueen's ni ersity in orthern reland has recei ed a million grant from foundations and from the nited ingdom esearch Partnership n estment und to build a entre for perimental Medicine, which, among its other facilities, will pro ide country-wide routine genotyping for patient care, and for clinical trials research . enotyping will be paid for by the country's health care ser ice. similar tumor genotyping ser ice is planned for other parts of the nited ingdom . nationwide network of regional cancer genotyping ser ices is under de elopment in rance and in ermany . n rance, regional centers are pro iding genotyping for actionable mutations and amplifications. o such national system, either for routine practice or for research purposes, is yet en isaged by the ational ancer nstitute, Medicare, insurers, or hospitals in the nited tates.
The only statewide effort in the . . to pro ide genotyping was undertaken in Te as in , as part of the state's billion, -year commitment to support cancer research. linical Trials etwork of Te as ( T eT , a statewide consortium of regional cancer centers and practices, was established, together with a sophisticated genomics center at Baylor ni ersity. The center intended to genotype up to , tumor specimens for multiple mutations, amplifications, and translocations, and planned to bank tumor samples for use in laboratory research and for identifying patients for trials. ts first clinical trials were set to begin this year. owe er, due to the comple political and financial hurdles of pulling these academic centers and practices together under one umbrella, that attempt failed, to the great disappointment of many of its participants. Because of serious administrati e mishaps, the state abruptly terminated T eT in anuary of and suspended its in estment in clinical trials of personali ed medicine . enomics-based medicine remains the most rational and promising new thrust of cancer therapeutics, and is largely the product of . . technology and medical science. The . . public in ested in the research that disco ered these treatments, and the critical trials were largely conducted in . . academic centers. enomic-based therapy offers the prospect of impro ing the quality of life and sur i al for thousands of cancer patients, for many of whom there is no effecti e alternati e therapy. n effect, it simplifies the current comple ity of cancer treatment Thus it seems illogical that, in the nited tates, and within the world's most e pensi e health care system, we cannot guarantee access to genotyping for all patients with lung cancer, colorectal cancer, melanoma, and other cancers. f a patient happens to go to the right cancer center, or finds the right clinical trial, he or she may ha e the tumor genotyped. owe er, if the patient is uninsured, or underinsured, or resides in an underser ed part of the country, the patient will not ha e access to this ser ice. The enthusiasm about personali ed medicine in the nited tates seems likely to be an unfulfilled promise for these many cancer patients.
f the tests in Table , and others surely to come, were routinely a ailable to all patients, many patients would be spared inappropriate and highly to ic treatment, outcomes of care would impro e, money would be sa ed, more patients would accrue to trials, trials would be completed, drugs would be appro ed more rapidly, and progress in cancer research would accelerate. t this point, the e idence for the financial benefit of personali ed therapeutics remains conjectural, but its alue seems intuiti e, gi en the higher response rates, longer time to progression, con enience, and lesser to icity of oral targeted therapies, as compared to infusional chemotherapy. e would be willing to wager that genomic testing does pay di idends for appro ed treatments and for allocating patients to rational trials. nd, for what better purpose ha e we established a national network of comprehensi e cancer centers than to do such testing on a regional basis t should be part of their mission. : Please see the accompanying article on pages -of this issue.
